Certified by Founder Lodge
Aviceda Therapeutics
United States - Cambridge, Massachusetts
START UP
1 Disclosed Funding Rounds $207,500,000
0 Participating Investments
-
Founded date
2018
-
Operating Status
Active
-
Last Funding Type
Seed
-
Company Type
For Profit
- Website
- Contact
- Social Links
The Future of Glyco-therapeutics
Aviceda Therapeutics is a disruptive clinical-stage biotech company focused on the next generation of immuno-modulators by harnessing the power of glycobio
| Date | Round | Raised | Participating Investors |
|---|---|---|---|
| January, 08 ,2025 | Series C | $207,500,000 |
Omega Funds
Enavate Sciences
Longitude Capital
TCGX
JEITO
Carmot Therapeutics, Inc.
Ozette Technologies
NAPIGEN, INC.
TrueBinding
Loopworm
Acurion, Inc. | $4,300,000 | (Apr 3, 2026)
EnerVenue | $300,000,000 | (Apr 3, 2026)
Monarch Quantum | $55,000,000 | (Apr 3, 2026)
Numos | $4,250,000 | (Apr 3, 2026)
Gander Robotics | $1,100,000 | (Apr 3, 2026)
